Applauds HHS For Appealing Ruling Against List Price Transparency Measure
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today after the U.S. Department of Health and Human services appealed a federal ruling blocking the implementation of a measure to require drug makers to disclose list prices in direct-to-consumer (DTC) advertising.
“Requiring Big Pharma to disclose list prices in direct-to-consumer advertising will help serve as a deterrent to their continued price-gouging and we applaud Secretary Azar and the Administration for standing by their DTC rule,” said CSRxP executive director Lauren Aronson. “Increasing transparency, along with boosting competition, will help hold Big Pharma accountable and lower prescription drug prices.”
“Lawmakers in Congress should also be commended for advancing several, bipartisan additional measures to boost transparency and shine a light on drug makers’ egregious practices,” Aronson continued. “Following the August recess, we encourage lawmakers to continue their work to ensure these and other market-based solutions to hold Big Pharma accountable and lower drug prices are passed into law.”